Trial Profile
Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+)), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-)) Metastatic Breast Cancer Patients: A Phase II Feasibility Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Aug 2022
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 25 Jun 2021 Status changed from active, no longer recruiting to completed.
- 05 Apr 2021 Planned End Date changed from 1 Mar 2021 to 1 Mar 2022.
- 05 Apr 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Mar 2022.